Medtech VC funding slowed in Q4, raking in $2.6 billion, down from $3 billion raised in Q3, according to PitchBook’s latest Emerging Tech Research. PE dealmaking was more resilient, with deal count up to 105 from 99 in 2022. The Q4 2023 Medtech Report lays out the ongoing challenges for dealmaking, though there is still funding available for startups in the later stages, such as Neuralink’s $323.2 million Series D. Brain therapy devices, which are less invasive than the brain-interface computers of Neuralink, could be the next big opportunity for investors.
Read the full article: PitchBook’s Q4 2023 Medtech Report //
Source: https://pitchbook.com/news/reports/q4-2023-medtech-report